High sustained virologic response in genotypes 3 and 6 with generic NS5A inhibitor and sofosbuvir regimens in chronic HCV in myanmar

• DOI: 10.1111/jvh.13133
• Publication Date: 2019-05-19T00:54:45Z
• Authors: Naomi Khaing Than...; Gayatri Nangia; Kyaw Thet Tun; Sithu Lin; Moe Zaw Maung; Khin Thuzar Myint; A. Mi Mi Kyaw; Soe Thiha Maung; Sithu Sein Win; Aung Hlaing Bwa; Bao‐Li Loza; Khin Maung Win; K. Rajender Reddy
• Keywords: Sofosbuvir; NS5A

Exclusive HCV therapy clinical trials with genotype 6 patients in high prevalence areas have been sparse. We analysed the safety and efficacy of two generic, pangenotypic NS5A/NS5B combination oral DAA regimens, primarily genotypes 3 6, a real-world setting: (a) daclatasvir/sofosbuvir (DCV/SOF) ± ribavirin (RBV) (b) Velpatasvir/sofosbuvir (VEL/SOF RBV). Between December 2015 November 2017, data from 522 were analysed, 311 whom treated DCV/SOF RBV for 12/24 weeks (genotype 3: n = 193, 6: 89) 211 VEL/SOF 83, 77). Overall SVR rates both (96.1%, 299/311) (95.3%, 201/211), there was good adverse event profile. Treatment naïve status inclusion (in advanced fibrosis/cirrhosis) significant independent predictors achieving SVR12, while type regimen not predictive. In this large cohort (n 276) 166; 127 unique subtype 6c-l), 94.9% 262/276) 95.2% 158/166), respectively, noted. conclusion, generic regimens highly effective safe, chronic Myanmar. These efficacious suggest that baseline testing can be eliminated moving forward. While may still needed those fibrosis/cirrhosis, global elimination strategy it would practical even if does compromise minority difficult to treat characteristics.